Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 8,920,383 protect, and when does it expire?

Patent ► Subscribe protects RYZODEG 70/30, TRESIBA, SAXENDA, LEVEMIR FLEXTOUCH, NORDITROPIN FLEXPRO, XULTOPHY 100/3.6, and NOVOLOG FLEXTOUCH, and is included in seven NDAs.

This patent has eight patent family members in nine countries.

Summary for Patent: ► Subscribe

Title:	Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Abstract:	A mechanism for preventing setting of a dose, which exceeds the amount of a medicament in a reservoir in an injection device. The device comprises a threaded piston rod, a limiter and a driver. The three elements are arranged such that during dose setting, the limiter is moved towards an end-of-contend position, wherein dose setting is limited. The invention comprises an accumulative and a non-accumulative embodiment. The invention further relates to a mechanism for prevention ejection of a dose exceeding the set dose.
Inventor(s):	Enggaard; Christian Peter (Hillerod, DK), Moller; Claus Schmidt (Fredensborg, DK), Markussen; Tom Hede (Bagsvaerd, DK)
Assignee:	Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:	11/996,409
Patent Claim Types: see list of patent claims	Use; Device;

Glossary

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	RS	Patent No.	Patent Expiration	Product
Novo Nordisk Inc	RYZODEG 70/30	insulin aspart; insulin degludec	SOLUTION;SUBCUTANEOUS	203313-001	Sep 25, 2015	RX	Yes	Yes	► Subscribe	► Subscribe	Y
Novo Nordisk Inc	TRESIBA	insulin degludec	SOLUTION;SUBCUTANEOUS	203314-001	Sep 25, 2015	RX	Yes	No	► Subscribe	► Subscribe	Y
Novo Nordisk Inc	TRESIBA	insulin degludec	SOLUTION;SUBCUTANEOUS	203314-002	Sep 25, 2015	RX	Yes	Yes	► Subscribe	► Subscribe	Y
Novo Nordisk Inc	SAXENDA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014	RX	Yes	Yes	► Subscribe	► Subscribe	Y
Novo Nordisk Inc	LEVEMIR FLEXTOUCH	insulin detemir recombinant	INJECTABLE;SUBCUTANEOUS	021536-005	Oct 31, 2013	RX	Yes	Yes	► Subscribe	► Subscribe	Y

This preview shows a limited data set Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	05016291	Jul 27, 2005

PCT Information
PCT Filed	July 17, 2006	PCT Application Number:	PCT/EP2006/007004
PCT Publication Date:	February 15, 2007	PCT Publication Number:	WO2007/017052

International Patent Family for Patent: ► Subscribe

Country	Document Number	Estimated Expiration
Japan	4827922	► Subscribe
Japan	2009502273	► Subscribe
Spain	2361563	► Subscribe
European Patent Office	1909870	► Subscribe
Denmark	1909870	► Subscribe

This preview shows a limited data set Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

DrugPatentWatch Database Preview